This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Jun 2011

Singapore’s HSA Approves Emergent's Biodefense Vaccine

Emergent BioSolutions’ biodefense vaccine BioThrax has been approved by the Singapore government’s Health Sciences Authority.

The Singapore government’s Health Sciences Authority (HSA) has approved Emergent BioSolutions’ BioThrax anthrax vaccine. The biodefense vaccine was recently approved by FDA.


BioThrax is currently the only FDA-licensed vaccine for the prevention of anthrax infection and is indicated for the active immunization of adults who are at high risk of exposure to anthrax.


To date, Emergent has delivered over 42 million doses of BioThrax to the U.S. government and continues to deliver additional doses under active procurement contracts.


Earlier this month Emergent announced that its investigational anthrax vaccine NuThrax? (AV7909; anthrax vaccine adsorbed with CPG 790

Related News